Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk

被引:73
作者
Abbas, Sascha [1 ]
Nieters, Alexandra [1 ]
Linseisen, Jakob [1 ]
Slanger, Tracy [1 ]
Kropp, Silke [1 ]
Mutschelknauss, Elke Jonny [2 ]
Flesch-Janys, Dieter [2 ]
Chang-Claude, Jenny [1 ]
机构
[1] German Canc Res Ctr, Div Canc Epidemiol, D-69120 Heidelberg, Germany
[2] Univ Clin Hamburg Eppendorf, Inst Med Biometr & Epidemiol, D-20246 Hamburg, Germany
关键词
D O I
10.1186/bcr1994
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Vitamin D receptor (VDR) genotypes may influence breast cancer risk by altering potential anticarcinogenic effects of vitamin D, but epidemiological studies have been inconsistent. Effect modification by serum 25-hydroxyvitamin D (25 [OH] D), the biomarker for vitamin D status in humans, has rarely been examined. Methods We assessed the effects of two frequently analyzed polymorphisms (FokI and TaqI) and two potentially functional variants (VDR-5132 and Cdx2) in the VDR gene, which thus far have not been analyzed with respect to breast cancer risk, on postmenopausal breast cancer risk in a population-based, case-control study including 1,408 patients (cases) and 2,612 control individuals (controls) matched for year of birth. Odds ratios (ORs) for breast cancer adjusted for potential confounders were calculated for genotypes and estimated haplotypes. Results No differences in serum 25(OD) D concentrations by VDR genotype were observed. None of the analyzed polymorphisms was associated with overall risk for postmenopausal breast cancer. However, the TaqI polymorphism was associated with a significantly increased risk for oestrogen receptor positive tumours (OR = 1.18, 95% confidence interval [Cl] = 1.00 to 1.38, comparing t allele carriers with noncarriers) but not for oestrogen receptor negative tumours (OR = 0.88, 95% CI = 0.69 to 1.13; P for interaction = 0.04). Haplotype analysis revealed the haplotype FtCA (FokI F, TaqI t, VDR-5132 C, Cdx2 A), which contains the TaqI t allele, to be associated with a significantly greater breast cancer risk as compared with the most frequent haplotype FTCG (OR = 1.43, 95% CI = 1.00 to 2.05). No significant interaction between VDR genotypes or haplotypes and 25(OH) D was observed. Conclusion Our results support potential effects of VDR polymorphisms on postmenopausal breast cancer risk and possible differential effects of receptor status of the tumour. However, further studies focusing on the influence of polymorphisms and haplotypes on VDR functionality, activity and concentration are needed.
引用
收藏
页数:11
相关论文
共 48 条
[31]   Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study [J].
McCullough, Marjorie L. ;
Stevens, Victoria L. ;
Diver, William R. ;
Feigelson, Heather S. ;
Rodriguez, Carmen ;
Bostick, Robin M. ;
Thun, Michael J. ;
Calle, Eugenia E. .
BREAST CANCER RESEARCH, 2007, 9 (01)
[32]   Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk [J].
Mikhak, Bahar ;
Hunter, David J. ;
Spiegelman, Donna ;
Platz, Elizabeth A. ;
Hollis, Bruce W. ;
Giovannucci, Edward .
PROSTATE, 2007, 67 (09) :911-923
[33]  
Newcomb PA, 2002, CANCER EPIDEM BIOMAR, V11, P1503
[34]   Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians [J].
Ogunkolade, BW ;
Boucher, BJ ;
Prahl, JM ;
Bustin, SA ;
Burrin, JM ;
Noonan, K ;
North, BV ;
Mannan, N ;
McDermott, MF ;
DeLuca, HF ;
Hitman, GA .
DIABETES, 2002, 51 (07) :2294-2300
[35]  
*R PROJ, R PROJ STAT COMP
[36]  
Shin MH, 2002, JNCI-J NATL CANCER I, V94, P1301, DOI 10.1093/jnci/94.17.1301
[37]   Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk [J].
Sillanpää, P ;
Hirvonen, A ;
Kataja, V ;
Eskelinen, M ;
Kosma, VM ;
Uusitupa, M ;
Vainio, H ;
Mitrunen, K .
PHARMACOGENETICS, 2004, 14 (04) :239-245
[38]  
Stoica A, 1999, J CELL BIOCHEM, V75, P640, DOI 10.1002/(SICI)1097-4644(19991215)75:4<640::AID-JCB10>3.0.CO
[39]  
2-8
[40]  
Swami S, 2000, CLIN CANCER RES, V6, P3371